Viral and cellular factors that target the promyelocytic leukemia oncogenic domains strongly activate a glucocorticoid-responsive promoter

Journal of Virology

Volumn 75, Issue 11, 2001, Pages 5391-5397

  Wienzek, Sandra ^a   Dobbelstein, Matthias ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEXAMETHASONE; GLUCOCORTICOID; HYBRID PROTEIN; MESSENGER RNA; ONCOPROTEIN; TAX PROTEIN; VIRUS PROTEIN;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T CELL LEUKEMIA; VIRUS CELL INTERACTION;

ADENOVIRIDAE; ADENOVIRUS E4 PROTEINS; CYTOMEGALOVIRUS; GLUCOCORTICOIDS; HELA CELLS; HUMANS; IMMEDIATE-EARLY PROTEINS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 0035033932     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.11.5391-5397.2001     Document Type: Article

References (38)

1. Ahn, J. H., E. J. Brignole III, and G. S. Hayward. 1998. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING finger-dependent cryptic transactivator function of PML. Mol. Cell. Biol. 18:4899-4913.
2. Ahn, J. H., and G. S. Hayward. 1997. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 71:4599-4613.
3. Angulo, A., and P. Ghazal. 1995. Regulation of human cytomegalovirus by retinoic acid. Scand. J. Infect. Dis. Suppl. 99:113-115.
4. Armentano, D., M. P. Smith, C. C. Sookdeo, J. Zabner, M. A. Perricone, J. A. St. George, S. C. Wadsworth, and R. J. Gregory. 1999. E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors. J. Virol. 73:7031-7034.
5. Armentano, D., J. Zabner, C. Sacks, C. C. Sookdeo, M. P. Smith, J. A. St. George, S. C. Wadsworth, A. E. Smith, and R. J. Gregory. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408-2416.
6. Bannister, A. J., and T. Kouzarides. 1996. The CBP coactivator is a histone acetyltransferase. Nature 384:641-643.
7. Boisvert, F. M., M. J. Hendzel, and D. P. Bazett-Jones. 2000. Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J. Cell Biol. 148:283-292.
8. Brough, D. E., C. Hsu, V. A. Kulesa, G. M. Lee, L. J. Cantolupo, A. Lizonova, and I. Kovesdi. 1997. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J. Virol. 71:9206-9213.
9. Carvalho, T., J. S. Seeler, K. Ohman, P. Jordan, U. Petterson, G. Akusjarvi, M. Carmo-Fonseca, and A. Dejean. 1995. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131:45-56.
10. Desbois, C., R. Rousset, F. Bantignies, and P. Jalinot. 1996. Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. Science 273:951-953.
11. Doucas, V., and R. M. Evans. 1999. Human T-cell leukemia retrovirus-Tax protein is a repressor of nuclear receptor signaling. Proc. Natl. Acad. Sci. USA 96:2633-2638.
12. Doucas, V., A. M. Ishov, A. Romo, H. Juguilon, M. D. Weitzman, R. M. Evans, and G. G. Maul. 1996. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10:196-207.
13. Doucas, V., M. Tini, D. A. Egan, and R. M. Evans. 1999. Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc. Natl. Acad. Sci. USA 96:2627-2632.
14. Huang, M. M., and P. Hearing. 1989. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J. Virol. 63:2605-2615.
15. Ishov, A. M., A. G. Sotnikov, D. Negorev, O. V. Vladimirova, N. Neff, T. Kamitani, E. T. Yeh, J. F. Strauss 3rd, and G. G. Maul. 1999. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147:221-234.
16. Kakizuka, A., W. H. Miller, Jr., K. Umesono, R. P. Warrell, Jr., S. R. Frankel, V. V. Murty, E. Dmitrovsky, and R. M. Evans. 1991. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66:663-674.
17. König, C., J. Roth, and M. Dobbelstein. 1999. Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55-kilodalton protein. J. Virol. 73: 2253-2262.
18. La Morte, V. J., J. A. Dyck, R. L. Ochs, and R. M. Evans. 1998. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc. Natl. Acad. Sci. USA 95:4991-4996.
19. Lusky, M., L. Grave, A. Dieterle, D. Dreyer, M. Christ, C. Ziller, P. Furstenberger, J. Kintz, D. A. Hadji, A. Pavirani, and M. Mehtali. 1999. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3. J. Virol. 73:8308-8319.
20. Mu, Z. M., X. F. Le, A. B. Glassman, and K. S. Chang. 1996. The biologic function of PML and its role in acute promyelocytic leukemia. Leuk. Lymphoma 23:277-285.
21. Mu, Z. M., X. F. Le, S. Vallian, A. B. Glassman, and K. S. Chang. 1997. Stable overexpression of PML alters regulation of cell cycle progression in HeLa cells. Carcinogenesis 18:2063-2069.
22. Muller, S., M. J. Matunis, and A. Dejean. 1998. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:61-70.
23. Nevels, M., B. Tauber, E. Kremmer, T. Spruss, H. Wolf, and T. Dobner. 1999. Transforming potential of the adenovirus type 5 E4orf3 protein. J. Virol. 73:1591-1600.
24. Ornelles, D. A., and T. Shenk. 1991. Localization of the adenovirus early region 1B 55-kilodalton protein during lytic infection: association with nuclear viral inclusions requires the early region 4 34-kilodalton protein. J. Virol. 65:424-429.
25. Quignon, F., F. De Bels, M. Koken, J. Feunteun, J. C. Ameisen, and H. de The. 1998. PML induces a novel caspase-independent death process. Nat. Genet. 20:259-265.
26. Rees, S., J. Coote, J. Stables, S. Goodson, S. Harris, and M. G. Lee. 1996. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. BioTechniques 20:102-104, 106, 108-110.
27. Rimsky, L., J. Hauber, M. Dukovich, M. H. Malim, A. Langlois, B. R. Cullen, and W. C. Greene. 1988. Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature 335:738-740.
28. Shen, Y., H. Zhu, and T. Shenk. 1997. Human cytomegalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins. Proc. Natl. Acad. Sci. USA 94:3341-3345.
29. Sternsdorf, T., T. Grotzinger, K. Jensen, and H. Will. 1997. Nuclear dots: actors on many stages. Immunobiology 198:307-331.
30. Sternsdorf, T., K. Jensen, and H. Will. 1997. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/ SUMO-1. J. Cell Biol. 139:1621-1634.
31. Strahle, U., M. Boshart, G. Klock, F. Stewart, and G. Schutz. 1989. Glucocorticoid- and progesterone-specific effects are determined by differential expression of the respective hormone receptors. Nature 339:629-632.
32. Torchia, J., D. W. Rose, J. Inostroza, Y. Kamei, S. Westin, C. K. Glass, and M. G. Rosenfeld. 1997. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677-684.
33. Wang, Z. G., L. Delva, M. Gaboli, R. Rivi, M. Giorgio, C. Cordon-Cardo, F. Grosveld, and P. P. Pandolfi. 1998. Role of PML in cell growth and the retinoic acid pathway. Science 279:1547-1551.
34. Wang, Z. G., D. Ruggero, S. Ronchetti, S. Zhong, M. Gaboli, R. Rivi, and P. P. Pandolfi. 1998. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:266-272.
35. Weis, K., S. Rambaud, C. Lavau, J. Jansen, T. Carvalho, M. Carmo-Fonseca, A. Lamond, and A. Dejean. 1994. Retinoic acid regulates aherrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76:345-356.
36. Yew, N. S., J. Marshall, M. Przybylska, D. M. Wysokenski, R. J. Ziegler, P. W. Rafter, C. Li, D. Armentano, and S. H. Cheng. 1999. Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3. Hum. Gene Ther. 10:1833-1843.
37. Zheng, P., Y. Guo, Q. Niu, D. E. Levy, J. A. Dyck, S. Lu, L. A. Sheiman, and Y. Liu. 1998. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature 396:373-376.
38. Zhong, S., P. Salomoni, and P. P. Pandolfi. 2000. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2:E85-E90.